This study investigates how using a combination of Ginkgo leaf extract, Dipyridamole injection, and antiplatelet therapy affects patients suffering from ST-segment elevation myocardial infarction (STEMI) after undergoing percutaneous coronary intervention (PCI)

Not Applicable

Completed

• Conditions: Percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI); Circulatory System

• Registration Number: ISRCTN15796398
• Lead Sponsor: The Affiliated Hospital of Weifang Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-12-31
• Study Start: 2024-04-07
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

1.It meets the diagnostic criteria of acute ST-segment elevation myocardial infarction in the Guidelines for Diagnosis and Treatment of acute ST-Segment Pickup Myocardial Infarction
2.The patient underwent emergency PCI treatment within 12 hours of onset;
3.Age =17 years old;
4.Complete clinical data.
5.The knowledge and consent of all participants in the study.

Exclusion Criteria

1.severe congenital heart disease;
2.Patients with severe liver and kidney dysfunction and malignant tumors;
3.Major surgery or trauma, cerebrovascular disease within 6 months;
4.People with cognitive or mental disorders.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cardiac function index: For the examination of cardiac function index, the cardiac output (CO) and cardiac index (cardiac index) were measured by color Doppler ultrasound (Minrui DC-N2S) before and after treatment in the two groups. CI, left ventricular ejection fraction (LVEF) and other cardiac function indicators.

Secondary Outcome Measures

Name	Time	Method
1. Bleeding risk: According to Bleeding Academic Research Consortium (BARC) bleeding classification criteria ,the number of cases of type 3 or type 5 bleeding during hospitalization and 30 days after discharge will be counted.<br>2. Embolization risk: thrombolysis in myocardial infarction (TIMI) blood flow rating and TIMI myocardial perfusion grade (TMPG) :TIMI blood flow grading and myocardial perfusion grading (TMPG) will be compared between the two groups before and after treatment.<br>3. Major adverse cardiac events (MACE) :Patients will follow up 30 days after hospitalization and discharge and MACE will be recorded, including cardiac death, myocardial infarction, recurrent angina pectoris, and revascularization.